Cargando…

Immune responses and reactogenicity after ChAdOx1 in individuals with past SARS-CoV-2 infection and those without

Detalles Bibliográficos
Autores principales:	Lim, So Yun, Kim, Ji Yeun, Lee, Jin Ah, Kwon, Ji-Soo, Park, Ji Young, Cha, Hye Hee, Suh, Mi Hyun, Lee, Hyun Jung, Kim, Hyeonju, Kim, Seungtaek, Bae, Seongman, Jung, Jiwon, Kim, Eui Ho, Jee, Youngmee, Kim, Sung-Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316626/ https://www.ncbi.nlm.nih.gov/pubmed/34332017 http://dx.doi.org/10.1016/j.jinf.2021.07.032

Ejemplares similares

Correlation between Reactogenicity and Immunogenicity after the ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccination
por: Lim, So Yun, et al.
Publicado: (2021)

Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines
por: Kim, Ji Yeun, et al.
Publicado: (2021)

Breakthrough infections and waning immune responses with ChAdOx1 nCoV‐19 or mRNA vaccine in healthcare workers
por: Lim, So Yun, et al.
Publicado: (2022)

Reactogenicity and Immunogenicity of the ChAdOx1 nCOV-19 Coronavirus Disease 2019 Vaccine in South Korean Healthcare Workers
por: Hyun, JongHoon, et al.
Publicado: (2022)

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
por: Al Bahrani, Salma, et al.
Publicado: (2021)

Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea
por: Bae, Seongman, et al.
Publicado: (2021)

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
por: Chang, Jer-Hwa, et al.
Publicado: (2022)

Immunogenicity after Second ChAdOx1 nCoV-19 (AZD1222) Vaccination According to the Individual Reactogenicity, Health Status and Lifestyle
por: Choi, Hyunji, et al.
Publicado: (2021)

Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity
por: Bae, Seongman, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
por: Schmidt, Tina, et al.
Publicado: (2021)

A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
por: Kim, Gyungah, et al.
Publicado: (2021)

Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
por: Hyun, Hakjun, et al.
Publicado: (2021)

Effect of short-term corticosteroid use on reactogenicity and immunogenicity of the first dose of ChAdOx1 nCoV-19 vaccine
por: Yang, Jinyoung, et al.
Publicado: (2021)

Effects of Short-Term Corticosteroid Use on Reactogenicity and Immunogenicity of the First Dose of ChAdOx1 nCoV-19 Vaccine
por: Yang, Jinyoung, et al.
Publicado: (2021)

COVID-19 Vaccination within the Context of Reactogenicity and Immunogenicity of ChAdOx1 Vaccine Administered to Teachers in Poland
por: Ganczak, Maria, et al.
Publicado: (2022)

Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis
por: Lin, Ting-Yun, et al.
Publicado: (2022)

A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination
por: Kim, Seok Hyun, et al.
Publicado: (2022)

Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19
por: Cha, Hye Hee, et al.
Publicado: (2022)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
por: Kim, Jinnam, et al.
Publicado: (2023)

Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19
por: Kim, Dong-In, et al.
Publicado: (2022)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
por: Berg, Adam, et al.
Publicado: (2021)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
por: Zhang, Cheng, et al.
Publicado: (2023)

Livedo reticularis following administration of ChAdOx1 nCoV-19 vaccine (AZD1222): a report of two cases
por: Kim, Joong Ho, et al.
Publicado: (2022)

Antibody Response Induced by Two Doses of ChAdOx1 nCoV-19, mRNA-1273, or BNT162b2 in Liver Transplant Recipients
por: Lim, So Yun, et al.
Publicado: (2022)

Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine
por: Kang, Yu Min, et al.
Publicado: (2021)

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study
por: Kohmer, Niko, et al.
Publicado: (2023)

Autoimmune encephalitis following ChAdOx1-S SARS-CoV-2 vaccination
por: Kwon, Hyeryung, et al.
Publicado: (2021)

Humoral Immune Response of Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Prime-Boost Vaccination against SARS-CoV-2 Variants in Korea
por: Lim, Heeji, et al.
Publicado: (2023)

COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19
por: Heo, Jung Yeon, et al.
Publicado: (2022)

Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine
por: Lim, Sung-Hee, et al.
Publicado: (2021)

Inflammatory myositis after ChAdOx1 vaccination
por: Maramattom, Boby Varkey, et al.
Publicado: (2021)

ChAdOx1-S vaccine for prevention of COVID-19
Publicado: (2021)

Factors related to the serious adverse events in patients visiting the emergency department after ChAdOx1 and mRNA COVID-19 vaccination
por: Jeong, Won Jung, et al.
Publicado: (2022)

Balancing the reactogenicity of the ChAdOx1 nCov-19 vaccine against COVID-19 and the urgent need of a large immunization in healthcare workers
por: Chouchana, Laurent, et al.
Publicado: (2022)

No correlation of neutralizing antibody titers against the Omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough Omicron infections among healthcare workers
por: Lee, Jeongjae, et al.
Publicado: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)

Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults
por: Dedroogh, Simon, et al.
Publicado: (2023)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations
por: Lee, Tae Hwan, et al.
Publicado: (2023)

Chronic spontaneous urticaria following ChAdOx1-S COVID-19 vaccination
por: Suan, Dan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ig84a2cmo3417fs91vcaqcdl7g